The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.
 
Angelika Terbuch
No Relationships to Disclose
 
Irene Moreno Candilejo
No Relationships to Disclose
 
Mariana Scaranti
No Relationships to Disclose
 
Daniel Bar
No Relationships to Disclose
 
Miriam Estevez Timon
No Relationships to Disclose
 
Malaka Ameratunga
No Relationships to Disclose
 
Joo Ern Ang
No Relationships to Disclose
 
Jonathan Ratoff
No Relationships to Disclose
 
Anna Minchom
No Relationships to Disclose
 
Udai Banerji
Employment - Institute of Cancer Research
Honoraria - Astellas Pharma; Lilly
Consulting or Advisory Role - Novartis; Phoenix Solutions
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Sierra Oncology
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Nina Tunariu
No Relationships to Disclose
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech